10-Q: Phibro Animal Health Soars 40% in Sales, Boosted by Acquisition

Phibro Animal Health Corporation reported a 40% surge in net sales and a significant increase in net income for the quarter ended September 30, 2025, largely driven by its recent Zoetis acquisition and strong Animal Health segment growth.

Summary

• Net sales increased by 40% to $363.9 million for the three months ended September 30, 2025, compared to $260.4 million in the prior year.
• Net income rose significantly to $26.5 million, up from $7.0 million in the same period last year.
• Diluted earnings per share (EPS) increased to $0.65 from $0.17 year-over-year.
• Adjusted EBITDA grew by 85% to $61.9 million, compared to $30.7 million in the prior year.
• The Animal Health segment's net sales increased by 55% to $283.5 million, with $80.5 million attributed to the Zoetis acquisition.
• Gross profit increased by 43% to $119.8 million, with gross margin expanding to 32.9% from 32.1%.
• Operating income surged by $33.6 million to $51.3 million.
• Cash and cash equivalents at the end of the period were $72.8 million, up from $68.0 million at June 30, 2025.
• Working capital improved to $498.8 million from $456.3 million.

Sentiment

Score: 8

Explanation: The company delivered exceptionally strong financial results, with significant growth in sales, net income, and Adjusted EBITDA, largely driven by a successful acquisition and organic segment growth. While geopolitical risks and regulatory challenges for a key product are notable, the overall financial performance and liquidity position are very positive.

Positives

• Net sales increased by 40% to $363.9 million, demonstrating strong top-line growth.
• Net income significantly improved to $26.5 million, up from $7.0 million in the prior year.
• Diluted EPS increased to $0.65, a substantial rise from $0.17 in the previous year.
• Adjusted EBITDA grew by 85% to $61.9 million, indicating robust operational performance.
• The Animal Health segment showed exceptional growth, with net sales increasing by 55% to $283.5 million, largely due to the successful integration and contribution of the Zoetis acquisition.
• Gross profit increased by 43% to $119.8 million, and gross margin expanded by 80 basis points to 32.9%, reflecting favorable product mix and increased average selling prices.
• Operating income more than doubled, increasing by $33.6 million to $51.3 million.
• Working capital improved to $498.8 million, and the current assets to current liabilities ratio strengthened to 2.98:1.
• Successful refinancing of debt in July 2024 and compliance with all financial covenants under the 2024 Credit Agreement.

Negatives

• Interest expense, net, increased by 58% to $12.1 million, primarily due to higher debt levels from the Zoetis acquisition and the expiration of a favorable interest rate swap agreement.
• Foreign currency losses, net, increased significantly to $2.9 million from $0.4 million in the prior year, driven by fluctuations in the Argentine Peso and Israeli New Shekel.
• Cash provided by operating activities decreased to $9.3 million from $12.6 million in the prior year.
• Cash used in investing activities increased substantially to $21.0 million from $2.9 million, reflecting higher capital expenditures and purchases of short-term investments.
• Performance Products segment net sales decreased by 7% to $17.4 million due to lower demand for personal care product ingredients.
• Corporate costs increased by $3.3 million due to higher headcount and other employee costs.

Risks

• **Geopolitical Conflicts**: Prolonged hostilities in Israel (Israel-Hamas conflict) could disrupt operations at three manufacturing sites and an office, which account for 16% of consolidated assets and 17% of consolidated net sales. Escalation could lead to supply chain disruptions, personnel/raw material shortages, and broader military conflict.
• **Regulatory Action on Mecadox (Carbadox)**: The FDA is pursuing withdrawal of approval for carbadox, an active ingredient in the Mecadox product. Phibro has requested an evidentiary hearing and filed a lawsuit to invalidate the order revoking the regulatory method. Loss of Mecadox sales, which were approximately $22 million for the twelve months ended September 30, 2025, would have an adverse effect on financial condition and results of operations.
• **Macroeconomic Conditions**: Adverse global economic conditions, international conflicts, and government trade policies (e.g., tariffs) could negatively impact business, introduce supply chain inefficiencies, and affect material costs and availability.
• **Russia-Ukraine Conflict**: Continuation or escalation could trigger additional sanctions, supply chain disruptions, macroeconomic impacts, foreign exchange and interest rate volatility, inflationary pressures, and heightened cybersecurity threats, despite limited direct exposure (1% of consolidated net sales).
• **Animal Disease Outbreaks**: Could significantly reduce demand for products or availability of raw materials.
• **Restrictions on Antibacterials**: Increasing prevalence of restrictions on antibacterial use in food-producing animals, including FDA Guidance 273 and similar global initiatives, could impact sales.
• **Competition**: Intense competition from large and small companies, some with greater resources.
• **Climate Change and Weather Conditions**: Potential adverse impact on operations and customer businesses.
• **Integration of Acquired Businesses**: Risks associated with successfully integrating acquired businesses, including the Zoetis MFA portfolio.
• **Indebtedness and Covenants**: Substantial debt levels and restrictions imposed by debt covenants.
• **Cybersecurity and Data Security**: Risks of breaches and attacks.

Future Outlook

The company expects adequate liquidity for at least the next twelve months, supported by cash on hand, operating cash flows, and available financing arrangements. However, the future ability to pay dividends is subject to financial performance and debt agreement limitations. The company is evaluating the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-01, ASU 2025-06) on future disclosures and financial statements.

Management Comments

• "While we initially had some disruption to our operations at the onset of the Israel-Hamas conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support."
• "While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years."
• "Phibro is continuing to defend swine producers ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox."
• "We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under the 2024 Credit Facility, will be sufficient to support our ongoing cash needs. At this time, we expect adequate liquidity for at least the next twelve months."

Industry Context

The animal health industry continues to be supported by global population growth, the expansion of the global middle class, and the need for productivity improvements in livestock production due to limitations in arable land and water supplies. The company's strategic acquisition of Zoetis's MFA portfolio aligns with the industry trend of enhancing product offerings and expanding global presence in key animal health categories. However, the industry faces ongoing challenges from changing disease pressures, weather conditions, and increasing regulatory scrutiny on products like antibacterials, as well as broader macroeconomic and geopolitical instability.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or global benchmarks to assess the results against industry standards.
• However, the significant growth in net sales and net income, particularly within the Animal Health segment, suggests strong performance relative to general industry growth trends, especially considering the strategic expansion through the Zoetis acquisition.
• The company's focus on diversified animal health and mineral nutrition products, alongside performance products, positions it within a competitive landscape that includes major players in animal pharmaceuticals and nutrition.

Legal Proceedings

• Ongoing litigation with the FDA regarding the withdrawal of approval for carbadox (Mecadox product), including a requested evidentiary hearing and a lawsuit filed in the D.C. Federal District Court.
• Party to various claims and lawsuits arising from the normal course of business, including product liabilities and payment disputes, which are not expected to have a material adverse effect.

Related Party Transactions

• Relatives of Jack C. Bendheim (Chairman, President, and CEO) received aggregate compensation and benefits of approximately $1.198 million for the three months ended September 30, 2025, and $0.781 million for the three months ended September 30, 2024, for services as employees or consultants.
• Jack C. Bendheim has sole authority to vote shares of stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

Stakeholder Impact

• **Shareholders**: Positive financial results (increased net income, EPS, and declared dividend) are beneficial. Geopolitical and regulatory risks could introduce volatility.
• **Employees**: Increased employee-related costs in Animal Health and Corporate suggest growth in workforce or compensation. Operations in Israel employ approximately 500 people, subject to regional conflict risks.
• **Customers**: Expanded product portfolio through the Zoetis acquisition offers broader offerings. Continued availability of Mecadox is crucial for swine producers. Supply chain stability is a focus amidst global conflicts.
• **Suppliers**: Potential for supply chain disruptions and inflationary pressures on raw materials due to macroeconomic conditions and conflicts.
• **Creditors**: Company is in compliance with debt covenants, and liquidity is deemed adequate for the next twelve months, which is positive for creditors.

Next Steps

• Continue to defend the safety and regulatory method of carbadox (Mecadox) through an evidentiary hearing and a lawsuit in the D.C. Federal District Court.
• Pay a cash dividend of $0.12 per share on Class A and Class B common stock on December 17, 2025, to stockholders of record on November 26, 2025.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-01, ASU 2025-06) for future fiscal years.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance in the latest quarter, with substantial increases in net sales, gross profit, net income, and Adjusted EBITDA. The strategic acquisition of Zoetis's MFA portfolio is clearly driving significant revenue growth and enhancing market position. While there are notable geopolitical risks, particularly concerning operations in Israel, and a material regulatory challenge with the Mecadox product, the company's strong operational execution, robust liquidity, and proactive defense of its product portfolio suggest a resilient business model. The current valuation, considering the strong growth trajectory and improved profitability, presents a compelling investment opportunity for long-term investors despite the identified risks.

Keywords

Animal Health, Medicated Feed Additives, MFA, Zoetis Acquisition, Nutritional Specialties, Vaccines, Mineral Nutrition, Performance Products, SEC Filing, 10-Q, Financial Results, Earnings, Phibro Animal Health, PAHC, Carbadox, Mecadox, FDA Regulation, Geopolitical Risk, Israel-Hamas Conflict, Debt Refinancing, Interest Rate Swaps, Supply Chain, Corporate Governance